David Guertin to Sirolimus
This is a "connection" page, showing publications David Guertin has written about Sirolimus.
Connection Strength
0.591
-
Guertin DA, Sabatini DM. An expanding role for mTOR in cancer. Trends Mol Med. 2005 Aug; 11(8):353-61.
Score: 0.243
-
Lamming DW, Ye L, Katajisto P, Goncalves MD, Saitoh M, Stevens DM, Davis JG, Salmon AB, Richardson A, Ahima RS, Guertin DA, Sabatini DM, Baur JA. Rapamycin-induced insulin resistance is mediated by mTORC2 loss and uncoupled from longevity. Science. 2012 Mar 30; 335(6076):1638-43.
Score: 0.096
-
Li H, Cotton JL, Guertin DA. Evaluating the therapeutic potential of mTOR inhibitors using mouse genetics. Methods Mol Biol. 2012; 821:329-47.
Score: 0.095
-
Guertin DA, Sabatini DM. The pharmacology of mTOR inhibition. Sci Signal. 2009 Apr 21; 2(67):pe24.
Score: 0.079
-
Guertin DA, Guntur KV, Bell GW, Thoreen CC, Sabatini DM. Functional genomics identifies TOR-regulated genes that control growth and division. Curr Biol. 2006 May 23; 16(10):958-70.
Score: 0.064
-
Sarbassov DD, Ali SM, Kim DH, Guertin DA, Latek RR, Erdjument-Bromage H, Tempst P, Sabatini DM. Rictor, a novel binding partner of mTOR, defines a rapamycin-insensitive and raptor-independent pathway that regulates the cytoskeleton. Curr Biol. 2004 Jul 27; 14(14):1296-302.
Score: 0.014